Results 21 to 30 of about 3,222,323 (307)

Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation

open access: yesAntiviral Therapy, 2023
Background Cytomegalovirus (CMV) infection is a frequent complication in haematopoietic cell/solid organ transplant (HCT/SOT) recipients. Previous studies report all-cause mortality rates of 31% and 50% in HCT/SOT recipients post-treatment initiation ...
Marielle Bassel   +5 more
doaj   +1 more source

JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B

open access: yesAntiviral Therapy, 2022
Background JNJ-73763989 comprises two hepatitis B virus (HBV)-specific, liver-targeted N-galactosamine-conjugated short interfering RNA triggers, JNJ-73763976 and JNJ-73763924.
Ed Gane   +15 more
doaj   +1 more source

Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations

open access: yesMolecular Therapy: Nucleic Acids, 2016
Primary microRNA (pri-miRNA) mimics are important mediators of effective gene silencing and are well suited for sustained therapeutic applications. Pri-miRNA mimics are processed in the endogenous miRNA biogenesis pathway, where elements of the secondary
Fiona T van den Berg   +3 more
doaj   +1 more source

The transformation of HIV therapy: One pill once a day

open access: yesAntiviral Therapy, 2022
A co-formulated, one pill once a day antiretroviral regimen (single-tablet regimen), containing efavirenz, emtricitabine, and tenofovir disoproxyl fumarate ( Atripla ), revolutionized the antiretroviral therapy landscape.
Madhu C Choudhary, John W Mellors
doaj   +1 more source

Antiviral therapy for human rabies

open access: yes, 2015
Human rabies is virtually always fatal despite numerous attempts at aggressive therapy. Most survivors received one or more doses of rabies vaccine prior to the onset of the disease.
Jackson, Alan C.   +2 more
core   +1 more source

Hepatitis B Virus Research in South Africa

open access: yesViruses, 2022
Despite being vaccine-preventable, hepatitis B virus (HBV) infection remains the seventh leading cause of mortality in the world. In South Africa (SA), over 1.9 million people are chronically infected with HBV, and 70% of all Black chronic carriers are ...
Mohube B. Maepa   +7 more
doaj   +1 more source

Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs

open access: yesMolecular Therapy: Nucleic Acids, 2017
Chronic infection with hepatitis B virus (HBV) remains a problem of global significance and improving available treatment is important to prevent life-threatening complications arising in persistently infected individuals. HBV is susceptible to silencing
Mohube Betty Maepa   +3 more
doaj   +1 more source

A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression

open access: yes, 2014
Background: The extent of the effect of antiviral therapy and its predictors in preventing hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C (CHC) or B (CHB) remain unclear.
鄭安理 ;許駿 ;胡賦強   +1 more
core   +1 more source

A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir

open access: yesAntiviral Therapy, 2022
Ergotism is a rare cause of peripheral vasoconstriction with varying presentation depending on the affected vessels. Coronary vasospasm is a rare, potentially fatal manifestation of ergotism.
Cheng-En Wu   +3 more
doaj   +1 more source

Antiviral therapy for the patients.

open access: yes, 2015
Data were present as number (%)a Two patients refused to receive antiviral therapy.b Antiviral therapy was applied in patients within 72 hours after enrollment.Antiviral therapy for the patients.
Zhiqiang Sun (658262)   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy